Story

Goldman Sachs Counsel Testifies She Saw No Evidence of Epstein's Crimes

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Goldman Sachs Counsel Testifies She Saw No Evidence of Epstein's Crimes

Summary

Goldman Sachs senior counsel Kathy Ruemmler told a House committee that she never witnessed any misconduct by Jeffrey Epstein and would have reported him to law enforcement if she had.

Text size
Background

Goldman Sachs senior counsel Kathy Ruemmler testified before a U.S. House committee on Wednesday, stating she would have reported convicted sex offender Jeffrey Epstein to law enforcement if she had been aware of his abuse of women or girls. The testimony is part of an ongoing congressional investigation into Epstein's activities and network.

Testimony Details

In her opening statement to the committee, Ruemmler asserted that she saw no indication of illegal behavior during her interactions with Epstein. Her testimony aimed to clarify her and the bank's knowledge of his conduct.

"First, I did not see any evidence of ongoing criminal conduct or misconduct of any kind by Epstein during the time I dealt with him," Ruemmler said, according to a Reuters report. She added, "Second, if I had seen or heard any evidence suggesting that he was abusing women or girls, I would have immediately reported him to law enforcement."

Sample IUX Markets – In-articleAd

Context of the Hearing

The hearing is part of a broader effort by lawmakers to understand the full scope of Epstein's criminal enterprise and scrutinize the individuals and institutions that may have enabled him. Financial institutions that provided services to Epstein have faced intense scrutiny over their due diligence and client-vetting processes.

Ruemmler's appearance before Congress underscores the continued reputational and legal fallout for major financial firms linked to the disgraced financier. The investigation seeks to determine what high-level executives knew about Epstein's activities and when they knew it.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST